{"product_id":"biolegend-329908","title":"Biolegend, 329908, APC anti-human CD279 (PD-1) Antibody, 100tests","description":"\u003cp\u003eProgrammed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.\u003cbr\u003e\n100tests\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.\u003cbr\u003e\nConcentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.\u003cbr\u003e\nExcitation Laser: Red Laser (633 nm)\u003cbr\u003e\nApplication Notes: Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin \u0026lt;0.01 EU\/µg).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA) Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA) Velu V, et al. 2007. J. Virol. 81:5819. (FA) Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA) Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity) Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC) Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG) Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Cheng K, et al. 2023. Int J Mol Sci. 24:. PubMed Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed Shi J, et al. 2023. Front Immunol. 14:1166052. PubMed Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed Imai H, et al. 2023. iScience. 26:106822. PubMed Xu C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:327. PubMed Gao Y, et al. 2023. JCI Insight. 8: . PubMed Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed Cao B, et al. 2022. Nat Commun. 13:6203. PubMed Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed Wang Z, et al. 2018. Nat Commun. 9:824. PubMed Cheng L, et al. 2021. Cancer Immunol Immunother. Online ahead of print. PubMed Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed Panwar B, et al. 2021. Genome Res. 31:659. PubMed Porsche CE, et al. 2021. JCI Insight. 6:. PubMed Jia X, et al. 2021. Clin Transl Immunology. 10:e1336. PubMed Daugan MV, et al. 2021. Cancer Immunol Res. 9:891. PubMed Yamaguchi A, et al. 2021. J Thorac Dis. 13:5430. PubMed Kraig E, et al. 2018. Exp Gerontol. 105:53. PubMed Liao JB, et al. 2021. J Immunother Cancer. 9:. PubMed Miles B, et al. 2015. Nat Commun. 6: 8608. PubMed Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed Todorova D, et al. 2020. EBioMedicine. 62:103120. PubMed Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed Huang Y, et al. 2020. FASEB J. 34:1768. PubMed Rodda LB, et al. 2020. Cell. 184(1):169-183.e17. PubMed Zhang J, et al. 2022. Nature. 609:369. PubMed Cai J, et al. 2021. eLife. 10:00. PubMed Martín–Gayo E, et al. 2020. Cell Rep. 30:984. PubMed Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed Xu H, et al. 2013. J Leukoc Biol. 93:943. PubMed Miles B, et al. 2016. PLoS Pathog. 12:e1005924. PubMed Rasmussen TA, et al. 2022. Cell Rep Med. 3:100766. PubMed Wang D, et al. 2017. Leukemia. 10.1038\/leu.2017.69. PubMed Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed Hirama T, et al. 2021. JCI Insight. 6:. PubMed Paul S, et al. 2021. Sci Transl Med. 13:. PubMed Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed Niu C, et al. 2018. Front Immunol. 9:1759. PubMed Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed Frasca D, et al. 2021. Front Immunol. 616650:12. PubMed Frasca D, et al. 2018. PLoS One. 13:e0197472. PubMed Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed Blackburn M, et al. 2015. J Immunol. 195: 3227 - 3236. PubMed Tian X, et al. 2015. J Immunol. 194:3873. PubMed Schultheiß C, et al. 2020. Immunity. 53(2):442-455.e4.. PubMed Zou F, et al. 2019. Nat Commun. 10:4109. PubMed Lecciso M, et al. 2017. Front Immunol. . 10.3389\/fimmu.2017.01918. PubMed Tan EE, et al. 2020. J Clin Invest. 130:5817. PubMed Chew G, et al. 2016. PLoS Pathog. 12: 1005349. PubMed Javed A, et al. 2015. PLoS One. 10: 0142086. PubMed\u003cbr\u003e\nRRID: AB_940473 (BioLegend Cat. No. 329907) AB_940475 (BioLegend Cat. No. 329908)\u003cbr\u003e\nStructure: Immunoglobulin superfamily\u003cbr\u003e\nDistribution: Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells\u003cbr\u003e\nLigand\/Receptor: B7-H1 (also known as PD-L1) and B7-DC (PD-L2)\u003cbr\u003e\nCell Type: B cells, Lymphocytes, T cells, Thymocytes, Tregs\u003cbr\u003e\nBiology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules\u003cbr\u003e\nMolecular Family: CD Molecules, Immune Checkpoint Receptors\u003cbr\u003e\nGene ID: 5133\u003cbr\u003e\nUniProt: View information about CD279 on UniProt.org\u003cbr\u003e\nClone: EH12.2H7\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: PD-1, PDCD1\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46863072559273,"sku":"329908","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-329908","provider":"Iright","version":"1.0","type":"link"}